EE335 A Multicenter Microcosting Study for COVID-19 in Brazil

This study aims to evaluate COVID-19 in-hospital costs and identify predictors at a patient-level in Brazil. is multicenter, prospective cohort that applied time-driven activity-based costing (TDABC) method five Brazilian reference centers for treatment. Patients hospitalized between March August 2020 (first wave of the disease) had their status confirmed by reverse transcription-polymerase chain reaction (RT–PCR) arrival were included our sample. The cost information was calculated patient level multivariable analyses clinical variability, considering ICU admissions patient’s comorbidities. 830 patients into analysis. median per I$4,428 (IQR 2,019; 11,464), demonstrated significative higher (p<0.001). I$11,596 6,016; 23,374), while those who ward 1,895 1,050; 3,317). Median day I$ 455 308; 711) total sample, I$690 I,528; 1,046) I$350 255; 449) non-ICU. Gender (p<0.001), Obesity (p = 0.005) Chronic pulmonary diseases 0.044) identified as hospital costs. By developing multicenter microcosting this allowed measure variability resource consumption patients’ according characteristics. These findings can sustain development financially sustainable health policies middle-income countries such